» Articles » PMID: 38349873

The Central Renin-angiotensin System: A Genetic Pathway, Functional Decoding, and Selective Target Engagement Characterization in Humans

Overview
Specialty Science
Date 2024 Feb 13
PMID 38349873
Authors
Affiliations
Soon will be listed here.
Abstract

Accumulating evidence suggests that the brain renin angiotensin system (RAS) plays a pivotal role in the regulation of cognition and behavior as well as in the neuropathology of neurological and mental disorders. The angiotensin II type 1 receptor (AT1R) mediates most functional and neuropathology-relevant actions associated with the central RAS. However, an overarching comprehension to guide translation and utilize the therapeutic potential of the central RAS in humans is currently lacking. We conducted a comprehensive characterization of the RAS using an innovative combination of transcriptomic gene expression mapping, image-based behavioral decoding, and pre-registered randomized controlled discovery-replication pharmacological resting-state functional magnetic resonance imaging (fMRI) trials (N = 132) with a selective AT1R antagonist. The AT1R exhibited a particular dense expression in a subcortical network encompassing the thalamus, striatum, and amygdalo-hippocampal formation. Behavioral decoding of the AT1R gene expression brain map showed an association with memory, stress, reward, and motivational processes. Transient pharmacological blockade of the AT1R further decreased neural activity in subcortical systems characterized by a high AT1R expression, while increasing functional connectivity in the cortico-basal ganglia-thalamo-cortical circuitry. Effects of AT1R blockade on the network level were specifically associated with the transcriptomic signatures of the dopaminergic, opioid, acetylcholine, and corticotropin-releasing hormone signaling systems. The robustness of the results was supported in an independent pharmacological fMRI trial. These findings present a biologically informed comprehensive characterization of the central AT1R pathways and their functional relevance on the neural and behavioral level in humans.

Citing Articles

Distinct neural computations scale the violation of expected reward and emotion in social transgressions.

Xu T, Zhang L, Zhou F, Fu K, Gan X, Chen Z Commun Biol. 2025; 8(1):106.

PMID: 39838081 PMC: 11751440. DOI: 10.1038/s42003-025-07561-7.


The central renin-angiotensin system: A genetic pathway, functional decoding, and selective target engagement characterization in humans.

Xu T, Chen Z, Zhou X, Wang L, Zhou F, Yao D Proc Natl Acad Sci U S A. 2024; 121(8):e2306936121.

PMID: 38349873 PMC: 10895353. DOI: 10.1073/pnas.2306936121.

References
1.
Stein M, Jain S, Simon N, West J, Marvar P, Bui E . Randomized, Placebo-Controlled Trial of the Angiotensin Receptor Antagonist Losartan for Posttraumatic Stress Disorder. Biol Psychiatry. 2021; 90(7):473-481. DOI: 10.1016/j.biopsych.2021.05.012. View

2.
Esteban O, Markiewicz C, Blair R, Moodie C, Isik A, Erramuzpe A . fMRIPrep: a robust preprocessing pipeline for functional MRI. Nat Methods. 2018; 16(1):111-116. PMC: 6319393. DOI: 10.1038/s41592-018-0235-4. View

3.
Jiang L, Zhu R, Bu Q, Li Y, Shao X, Gu H . Brain Renin-Angiotensin System Blockade Attenuates Methamphetamine-Induced Hyperlocomotion and Neurotoxicity. Neurotherapeutics. 2018; 15(2):500-510. PMC: 5935642. DOI: 10.1007/s13311-018-0613-8. View

4.
Narayanaswami V, Somkuwar S, Horton D, Cassis L, Dwoskin L . Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked [³H]dopamine and [³H]norepinephrine release. Biochem Pharmacol. 2013; 86(5):656-65. PMC: 4048931. DOI: 10.1016/j.bcp.2013.06.025. View

5.
Lago T, Brownstein M, Page E, Beydler E, Manbeck A, Beale A . The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study. Psychopharmacology (Berl). 2021; 238(9):2393-2403. PMC: 8376758. DOI: 10.1007/s00213-021-05861-4. View